Nephrotoxicity induced by piperacillin-tazobactam in late elderly Japanese patients with nursing and healthcare associated pneumonia

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 12, 2014, Pages 1971-1976

  Karino, Fumi ^a   Nishimura, Nobuhiro ^b   Ishihara, Noriyuki ^b   Moriyama, Hidehiko ^b   Miura, Kiyotaka ^a   Hamaguchi, Shunichi ^a   Sutani, Akihisa ^a   Kuraki, Takashige ^a   Ikawa, Kazuro ^c   Morikawa, Norifumi ^c   Naora, Kohji ^b   Isobe, Takeshi ^a  

^a SHIMANE UNIVERSITY   (Japan)

^b SHIMANE UNIVERSITY HOSPITAL   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Japanese late elderly patient; Nephrotoxicity; Nursing and healthcare associated pneumonia; Piperacillin tazobactam

Indexed keywords

C REACTIVE PROTEIN; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

AGED; AREA UNDER THE CURVE; ARTICLE; BODY TEMPERATURE; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; JAPANESE (PEOPLE); KIDNEY FAILURE; LEUKOCYTE COUNT; LIVER TOXICITY; MALE; NEPHROTOXICITY; NURSING AND HEALTHCARE ASSOCIATED PNEUMONIA; PILOT STUDY; PNEUMONIA; PSEUDOMEMBRANOUS COLITIS; RISK ASSESSMENT; THORAX RADIOGRAPHY; VERY ELDERLY; AGING; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMICALLY INDUCED; CROSS INFECTION; KIDNEY DISEASE; PNEUMONIA, BACTERIAL;

AGED; AGED, 80 AND OVER; AGING; ANTI-BACTERIAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS INFECTION; FEMALE; HUMANS; KIDNEY DISEASES; MALE; PENICILLANIC ACID; PIPERACILLIN; PNEUMONIA, BACTERIAL;

EID: 84919723182     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b14-00362     Document Type: Article

References (20)

1. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med., 171, 388-416 (2005).
2. Kohno S, Imamura Y, Shindo Y, Seki M, Ishida T, Teramoto S, Kadota J, Tomono K, Watanabe A. Clinical Practice Guidelines for Nursing- and Healthcare-Associated Pneumonia (NHCAP). Respir. Investig., 51, 103-126 (2013).
3. Ministry of Health, Labour and Welfare of Japan. Specified Report of Vital Statistics in fiscal year 2007.
4. Karino F, Miura K, Fuchita H, Koba N, Nishikawa E, Hotta T, Okimoto T, Iwamoto S, Tsubata Y, Tada M, Hamaguchi S, Honda T, Ohe M, Sutani A, Kuraki T, Takeyama H, Isobe T. Efficacy and safety of piperacillin/tazobactam versus biapenem in late elderly patients with nursing- and healthcare-associated pneumonia. J. Infect. Chemother., 19, 909-915 (2013).
5. Johnson CA, Halstenson CE, Kelloway JS, Shapiro BE, Zimmerman SW, Tonelli A, Faulkner R, Dutta A, Haynes J, Greene DS, Kuye O. Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin. Pharmacol. Ther., 51, 32-41 (1992).
6. Shiba K. Dosage and administration schedule adjustment of tazobactam/piperacillin based on PK-PD analysis in patients with renal dysfunction. Jpn. J. Chemother., 59, 359-365 (2011).
7. Hamada Y, Takahashi S, Hirayama T, Sunakawa K, Kuroyama M. Population pharmacokinetics of tazobactam/piperacillin in Japanese patients with community-acquired pneumonia. Jpn. J. Antibiot., 66, 189-203 (2013).
8. Miyashita N, Matsushima T, Oka M; Japanese Respiratory Society. The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. Intern. Med., 45, 419-428 (2006).
9. Gilbert DN, Moellering RC, Eliopoulos GM, Chambers HF, Saag MS. The Sanford guide to antimicrobial therapy 2011, 41st edition. Antimicrobial Therapy, Inc., Sperryville, VA, p. 192 (2011).
10. Di Giovamberardino G, Ferrannini M, Testore GP, Federici G, Pastore A. High performance liquid chromatographic determination of plasma free and total tazobactam and piperacillin. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 877, 86-88 (2009).
11. Saito A, Miki F, Oizumi K, Rikitomi N, Watanabe A, Koga H, Niki Y, Kusano N. Clinical evaluation methods for new antimicrobial agents to treat respiratory infections: Report of the Committee for the Respiratory System, Japan Society of Chemotherapy. J. Infect. Chemother., 5, 110-123 (1999).
12. Ministry of Health, Labour and Welfare of Japan. Classification criteria of severity of adverse drug reactions. pp. 100-110 (2003).
13. Klevens RM, Edwards JR, Richards CL Jr, Horan TC, Gaynes RP, Pollock DA, Cardo DM. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep., 122, 160-166 (2007).
14. Watanabe A, Aoki N, Niki Y, Saito A, Kohno S, Shiba K. Clinical pharmacological study of tazobactam/piperacillin in patients with community-acquired pneumonia. Jpn. J. Chemother., 58, 11-28 (2010).
15. Watanabe A, Aoki N, Chiba K, Niki Y, Saito A. Kohno, Kadota J, Shiba K. Comparative phase III tazobactam/piperacillin and ceftazidime study in the treatment of community-acquired pneumonia. Jpn. J. Chemother., 58, 29-49 (2010).
16. Ito I, Kadowaki S, Tanabe N, Haruna A, Kase M, Yasutomo Y, Tsukino M, Nakai A, Matsumoto H, Niimi A, Chin K, Ichiyama S, Mishima M. Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk for aspiration: comparison with imipenem/cilastatin. Pulm. Pharmacol. Ther., 23, 403-410 (2010).
17. Tsukada H, Sakai K, Cho H, Kimura Y, Tetsuka T, Nakajima H, Ito K. Retrospective investigation of the clinical effects of tazobactam/piperacillin and sulbactam/ampicillin on aspiration pneumonia caused by Klebsiella pneumoniae. J. Infect. Chemother., 18, 715-721 (2012).
18. Mandell Gerald L, Bennett John E. Dolin Raphael. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th edition, Churchhill Livingston Elsevier, Philadelphia, PA, p. 314 (2009).
19. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr T, Andersen MH, Thornberg KJ, Løken J, Steensen M, Fox Z, Tousi H, Søe-Jensen P, Lauritsen AØ, Strange DG, Reiter N, Thormar K, Fjeldborg PC, Larsen KM, Drenck NE, Johansen ME, Nielsen LR, Ostergaard C, Kjær J, Grarup J, Lundgren JD. Procalcitonin and Survival Study (PASS) Group. Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial. BMJ Open, 2, e000635 (2012).
20. Casu GS, Hites M, Jacobs F, Cotton F, Wolff F, Beumier M, De Backer D, Vincent JL, Taccone FS. Can changes in renal function predict variations in β-lactam concentrations in septic patients? Int. J. Antimicrob. Agents, 42 , 422-428 (2013).